0 Items

Happy New YearImmunochemistry Technologies (ICT) and its employees have once again, embraced the Holiday Season.  Along with all of the traditional seasonal celebration activities that occur this time of year, we have also begun to make plans for our annual ICT year-end post-New Year’s celebration.  Festivities are definitely in order as we wrap up another successful business calendar year.  The year 2015 brought about, in terms of gross revenues, our highest yearly sales numbers since the company was founded back in September 1994.  We foresee continued growth in 2016 sales revenues as we further expand ICT’s CellMetrix line of fluorescence-based, cell-health-status-assessment products.  Cell culture populations destined for use as living cell indicators of an experimental treatment protocol, could be prescreened with a predetermined set of critical health status parameter CellMetrix line assays.  This in turn would allow prequalification of these cells as being in sufficiently good health to provide an accurate depiction of the experimental outcome.  Additionally, during the 2016 calendar year, ICT intends to expand its fluorogenic substrate mediated assay platform product line to accommodate the detection and monitoring of other critical enzyme-mediated cascade systems.

As we embark on our 22nd year of providing: 1) high quality ELISA development products and services, and 2) fluorescence-based cell physiology parameter assessment kits serving the needs of the living cell-model-dependent, academic and industrial R&D communities, we hope to further expand and improve our product capabilities within each of these two different  detection technology platforms. For this to happen however, we will continue to rely on our dedicated and highly motivated staff members and consultants.  It has always been my philosophy that a company is nothing without its employees.  Even the most well thought out plans laid out by company executives or boards of directors, would never come to fruition were it not for the contributions of their competent and loyal employees.  Fortunately, ICT has had the foresight to staff itself with these types of people.   Based upon this observation alone, I foresee a bright future for ICT going into 2016 and beyond.

Happy New Year!

Brian Lee

 

Brian Lee, Ph.D
President, ImmunoChemistry Technologies